Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 4/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.39 |
| ▸ | USP5 | P45974 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 8/20 | 0.36 |
| ▸ | JAK1 | P23458 | 8/20 | 0.36 |
| ▸ | TYK2 | P29597 | 8/20 | 0.36 |
| ▸ | JAK3 | P52333 | 8/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5374213 | 0.83 | F2 (0.50) | PARP14F2OPRM1OPRD1 | |
| SCHEMBL5732645 | 0.73 | F2 (0.50) | PARP14F2OPRM1OPRD1 | |
| SCHEMBL7076354 | 0.72 | MMP2 (0.39) | PARP14PARP10USP5CA12CA1 | |
| SCHEMBL5203573 | 0.69 | F2 (0.57) | PARP14F2CA12CA1CA2 | |
| SCHEMBL7375632 | 0.67 | ROCK2 (0.46) | ROCK2PIM1PIM3JAK2JAK1 | |
| SCHEMBL7509753 | 0.64 | ROCK2 (0.46) | ROCK2PIM1PIM3OPRM1OPRD1 | |
| SCHEMBL5734925 | 0.64 | F2 (0.47) | ROCK2PIM1PIM3F2 | |
| SCHEMBL27303418 | 0.63 | PARP10 (0.46) | PARP14PARP10CA12CA1CA2 | |
| SCHEMBL5733400 | 0.63 | ROCK2 (0.41) | ROCK2PIM1PIM3JAK2JAK1 | |
| SCHEMBL30098896 | 0.63 | AR (0.64) | ROCK2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6340685-B1 | ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-01-22 | — | — | US | disclosed |
| US-6130235-A | PIPERIDINE MOIETIES COUPLED TO INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE. | SCIOS INC. (US) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | RCOR1, NR3C2, CNR1 | PARP14 2130/4885PARP10 2873/4885USP5 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.